Marinus Pharmaceuticals, Inc. (MRNS)
Pre-market:
- Zacks
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
- Business Wire
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
RADNOR, Pa., April 15, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following an interim analysis.
- Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
RADNOR, Pa., April 05, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to two new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 47,400 shares of its common stock (the "Common Stock") as inducements material to the employees entering
